Autonomic Function Testing
CARDIAC AUTONOMIC FUNCTION TESTING (ANS)
The VitalScan diagnostic test provides next generation non‐invasive patient diagnostics within minutes. The FDA cleared equipment is used by physicians to help identify diseases that may be associated with Autonomic Nervous System, Autonomic Regulation and Autonomic Function.
TESTING THE AUTONOMIC NERVOUS SYSTEM
Testing the autonomic nervous system can identify clinical autonomic disorders uncover major illness and other hidden diseases, such as:
Sudden Death
Silent Heart Attack
Hypertension
Cardiac Autonomic Neuropathy
Vascular Abnormalities
Orthostatic Hypotension
Syncope
WHY ANS TEST?
According to Published Studies1 “Cardiovascular autonomic neuropathy occurs in about 17% of patients with type 1 diabetes and 22% of those with type 2”
“Of patients with symptomatic autonomic dysfunction, 25% to 50% die within 1 to 5 years of diagnosis.”
“A patient’s history and physical examination are ineffective for early detection of CAN, and therefore noninvasive tests that have demonstrated efficacy are required”.
“Screening for Autonomic Neuropathy should be instituted at Diagnosis of Type 2 Diabetes and 5 years after the diagnosis of type 1 Diabetes ‐ 2005 ADA Standard of Diabetes Care”
“Although it can cause severe cardiovascular problems and sudden death, surveys show that only 2% of people with diabetes are tested for cardiovascular autonomic neuropathy (CAN)”.
BENIFITS OF VITAL SCAN ANS
Presents a quick and reliable supplementary assessment of basic health risk factors.
Assesses the balance between the activities of the sympathetic and parasympathetic branches
of the autonomic nervous system.
Reliably discovers ventricular and supraventricular extra systoles.
Assesses accumulated physical and mental stress.
Assesses physical training needs based upon an individual’s personal fitness levels.
Reveals development of possible health risks.
Provides early indications of health risks for quick detection and prevention of illness, disease,
and progressive stress conditions before onset and development.
Efficiently screen mass population to detect potential risks and reserve costly, full medical
checkups for only those exhibiting health threats